Tagged with GEN

Belgium Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV, and his goals around making an impact for patients in Benelux over the coming years.   If you see the…

USA Speaking at the 2023 BIO International Convention Chris Viehbacher who joined Biogen as CEO only a few months ago, criticised the US’s Inflation Reduction Act (IRA), legislation that will allow Medicare to negotiate prices for the drugs it spends the most on as of 2026. Viehbacher, who was brought in…

UAE Tarek Thaher of MS Pharma, a leading generics firm in the Middle East and Africa, describes the benefits of manufacturing localisation in the UAE, his excitement about the firm’s growth trajectory based on a host of upcoming product launches, and its moves into the biosimilars space.   All in all,…

Europe As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for the coming year, including the lessons to be taken from the pandemic response, why antimicrobial resistance must not be neglected,…

UAE Tabuk Pharmaceuticals is a Saudi success story, now established as one of the GCC region’s leading private pharmaceutical companies. Gulf Manager Ossama Salah Ramadan explains what attracted him to the firm, his current strategic objectives in line with the company’s global growth goals, and some of the key local trends…

Belgium Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the company’s biosimilar portfolio has the potential to contribute to significant savings for the healthcare system.   Improving the evaluation process…

Europe In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the Agency’s approach to antimicrobial resistance, and highlights how it hopes to contribute to a stronger European clinical trials ecosystem.  …

Poland With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market in the European Union. Having demonstrated steady year-on-year growth, the market, with its strong generics-centred local players, is set to…

China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…

Argentina Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful strategy predicated on customising its offering to each country and balancing local management autonomy with a strong company culture.  …

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

Colombia Tecnoquímicas recently invested over USD 250 million in its Colombian manufacturing plants, signifying the company’s continuing faith in its home market. Executive Vice-President Emilio Sardi Aparicio outlines the regulatory and access landscape in Colombia today, how the firm’s international footprint within Latin America has evolved, and its approach to the…